凝血[酉每]抑制劑市場:各類型，各用途，各地區:規模，佔有率，展望，機會分析，2023年～2030年

Thrombin Inhibitor Market, By Type, By Application (Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Others ), and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年06月14日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

市場動態:

深靜脈血栓(DVT)、肺栓塞(PE) 和心房顫動(AF) 的患病率/發病率不斷增加，對安全有效治療的需求增加（由於全世界人們的認識不斷提高），研究和開發（研發）的增加）和新型抗凝劑的推出是預計推動全球凝血?抑製劑市場增長的主要因素。

本調查的主要特徵

本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球凝血[酉每]抑制劑市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球凝血[酉每]抑制劑市場的主要參與者之企業簡介。
藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
全球凝血[酉每]抑制劑市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者可以透過全球凝血[酉每]抑制劑市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

Thrombin inhibitors are anticoagulants (or are a class of medication that act as anticoagulants) that bind to and inhibit the activity of thrombin therefore prevent blood clot formation. They are used to prevent arterial and venous thrombosis, as well as to prevent and treat deep vein thrombosis and are used as prophylaxis in atrial fibrillation to avoid thromboembolism.

Market Dynamics:

Increasing prevalence/incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF), rise in demand for safe and effective treatment (due to increasing awareness among people worldwide), increase in research and development (R&D), and introduction of novel anticoagulants are major factors expected to propel growth of the global thrombin inhibitor market.

For instance, in June 2018, Mylan N.V. announced the U.S. launch of Bivalirudin for Injection, a generic version of Angiomax. The product, 250 mg single-dose vial, is a direct thrombin inhibitor indicated for use as an anticoagulant in patients. Mylan is offering Bivalirudin to its hospital and institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).

Key features of the study:

This report provides in-depth analysis of the global thrombin inhibitor market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global thrombin inhibitor market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, GlaxoSmithKline plc, AbbVie Inc., Portola Pharmaceuticals, Inc., CSL Behring, Johnson & Johnson, Sanofi S.A., Bayer AG, Pfizer Inc., Bristol Myers Squibb, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, and Aspen Pharmacare Holdings Limited, among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global thrombin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global thrombin inhibitor market.

Detailed Segmentation:

Global Thrombin Inhibitor Market, By Type:
- Direct Thrombin Inhibitors
- Indirect Thrombin Inhibitors
Global Thrombin Inhibitor Market, By Application:
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Atrial Fibrillation (AF)
- Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
Global Thrombin Inhibitor Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles:
- Eisai Co., Ltd.
- Merck & Co., Inc.
- Novartis International AG
- GlaxoSmithKline plc
- AbbVie Inc.
- Portola Pharmaceuticals, Inc.
- CSL Behring
- Johnson & Johnson
- Sanofi S.A.
- Bayer AG
- Pfizer Inc.
- Bristol Myers Squibb
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company
- Aspen Pharmacare Holdings Limited

Market Dynamics
- Increasing prevalence or incidence of DVT, PE, and AF
- Lack of awareness among people about thrombin inhibitor
- Increasing demand for safe/effective thrombin inhibitors
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Thrombin Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Thrombin Inhibitor Market, By Type, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Direct Thrombin Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
Indirect Thrombin Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)

6. Global Thrombin Inhibitor Market, By Application, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Deep Vein Thrombosis (DVT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
Pulmonary Embolism (PE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
Atrial Fibrillation (AF)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)

7. Global Thrombin Inhibitor Market, By Geography, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)

8. Competitive Landscape

Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc.
Novartis International AG
GlaxoSmithKline plc
AbbVie Inc.
Portola Pharmaceuticals, Inc.
CSL Behring
Johnson & Johnson
Sanofi S.A.
Bayer AG
Pfizer Inc.
Bristol Myers Squibb
Boehringer Ingelheim GmbH
Daiichi Sankyo Company
Aspen Pharmacare Holdings Limited
Analyst Views